Evidence map›Paper›PMID 32519302›Full record

ReviewProtein & cell2020

Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.

Hua Qin, Andong Zhao

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Protein & cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05658692 (Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome), which is not on this map. Cited by 89 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 6 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05658692 phase4unknown statusnot on this mapstarted 2022, after this paper: background citation

Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome

TypeinterventionalSponsorSecond Affiliated Hospital, Zhejiang University, School of MedicineRan2022 to 2023Enrolled1,000ConditionsAcute Respiratory Distress SyndromeArmsprotective ventilation, prone position ventilation, glucocorticoid therapy, restrictive fluid resuscitation, Thymosin Alpha
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 6 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Asthma and stem cell therapy.World journal of stem cells · 2025
    Review
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hua QinResearch Center for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, 100853, China. qinh0116@126.com.ORCID http://orcid.org/0000-0002-5128-8986
Andong ZhaoResearch Center for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, 100853, China.
Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple organ failure. Despite advances in supportive care approaches, ARDS is still associated with high mortality and morbidity. Mesenchymal stem cell (MSC)-based therapy may be an potential alternative strategy for treating ARDS by targeting the various pathophysiological events of ARDS. By releasing a variety of paracrine factors and extracellular vesicles, MSC can exert anti-inflammatory, anti-apoptotic, anti-microbial, and pro-angiogenic effects, promote bacterial and alveolar fluid clearance, disrupt the pulmonary endothelial and epithelial cell damage, eventually avoiding the lung and distal organ injuries to rescue patients with ARDS. An increasing number of experimental animal studies and early clinical studies verify the safety and efficacy of MSC therapy in ARDS. Since low cell engraftment and survival in lung limit MSC therapeutic potentials, several strategies have been developed to enhance their engraftment in the lung and their intrinsic, therapeutic properties. Here, we provide a comprehensive review of the mechanisms and optimization of MSC therapy in ARDS and highlighted the potentials and possible barriers of MSC therapy for COVID-19 patients with ARDS.

Indexed as

BetacoronavirusMesenchymal Stem Cell TransplantationPandemicsAdoptive TransferAlveolar Epithelial CellsAnimalsApoptosisBody FluidsCD4-Positive T-LymphocytesClinical Trials as TopicCoinfectionCoronavirus InfectionsCOVID-19Disease Models, AnimalEndothelial CellsExtracorporeal Membrane OxygenationInflammation Mediatorsacute respiratory distress syndromecell therapyCOVID-19mesenchymal stem cellspneumoniaSARS-CoV-2

Identifiers

PMID32519302
PMCPMC7282699
OpenAlexW3033628872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.